The coronavirus responsible for COVID‐19, SARS‐CoV‐2, utilizes a viral membrane spike
protein for host cell entry. For the virus to engage in host membrane fusion, SARS‐CoV‐2 …

Background In vitro drug screening studies have indicated that camostat mesilate (FOY-305)
may prevent SARS-CoV-2 infection into human airway epithelial cells. This study was …

The currently unfolding coronavirus pandemic threatens health systems and economies
worldwide. The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …

Background Antivirals are needed to combat the COVID-19 pandemic, which is caused by
SARS-CoV-2. The clinically-proven protease inhibitor Camostat mesylate inhibits SARS …

Novel coronavirus disease (COVID-19), caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), is a global threat. Antivirals and vaccines need to be …

ABSTRACT The coronavirus disease 2019 (COVID-19) pandemic has caused significant
morbidity and mortality on a global scale. The etiologic agent, severe acute respiratory …

The need for proven disease-specific treatments for the novel pandemic coronavirus SARS-
CoV-2 necessitates a worldwide search for therapeutic options. Since the SARS-CoV-2 virus …

Hydroxychloroquine, used to treat malaria and some autoimmune disorders, potently inhibits
viral infection of SARS coronavirus (SARS-CoV-1) and SARS-CoV-2 in cell-culture studies …

The entry of the coronavirus SARS-CoV-2 into human lung cells can be inhibited by the
approved drugs camostat and nafamostat. Here we elucidate the molecular mechanism of …

Background The trans-membrane protease serine 2 (TMPRSS2) is essential for severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cell entry and infection. Efficacy …